Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Q1 2021 Earnings Presentation
15 slides from Abcellera Biologics's earnings presentation, May 13, 2021
Slide 1: Q1 2021 Business Update
ellera Q1 2021 BUSINESS UPDATE May 13, 2021
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently av
Slide 3: Vision: build the world's most advanced antibody discovery engine
Q 1 2 0 2 1 B U S I N E S S U P D A T E . V IS ION We have a bold vision – TO BUILD THE WORLD’S MOST TECHNOLOGICALLY ADVANCED ANTIBODY DRUG DISCOVERY ENGINE, DEFINING THE STATE-OF-THE-ART FOR THE INDUSTRY, NOT JUST TODAY, BUT FOR DECADES TO COME.
Slide 4: Expand Capabilities. Build Capacity. Extend Commercial Reach.
Q1 2021 BUSINESS UPDATE. GROWTH STRATEGY EXPAND CAPABILITIES. BUILD CAPACITY. EXTEND COMMERCIAL REACH. Our key growth strategies for achieving our long-term objectives include: 1 2 3 4 5 Increase programs Forward integration Scale teams Further technology Improve speed, under contract of our tech st
Slide 5: Q1 2021 Highlights
Q 1 2 0 2 1 B U S I N E S S U P D A T E . HIGHL IGHTS Expanded 16 16 new programs under contract (PUCs) existing & new NEW PROGRAMS partnerships Gilead Sciences into a new UNDER CONTRACT multi-year, multi-target agreement. 119 Diversified hundreds of royalty positions CUMULATIVE PROGRAMS program por
Slide 6: Our New Tech Campus: Scaling Innovation, Creativity & Technology
Q 1 2 0 2 1 B U S I N E S S U P D A T E . FA C IL ITIES OUR NEW TECH CAMPUS: SCALING INNOVATION, CREATIVITY & TECHNOLOGY
Slide 7: Bamlanivimab: The Most Broadly Used COVID-19 Antibody in the World
Q1 2021 BUSINESS UPDATE. COVID-19 PROGRAM BAMLANIVIMAB:THE MOST BROADLY USED COVID-19 ANTIBODY IN THE WORLD Since being authorized for emergency use by the US FDA in November 2020, bamlanivimab has prevented hospitalizations and death: • 400K+ patients treated • 20K+ patients kept out of hospital Li
Slide 8: LY-CoV1404: A Potential Long-Term Solution for COVID-19
Q 1 2 0 2 1 B U S I N E S S U P D A T E . C OV ID-19 P ROGRA M LY-COV1404: A POTENTIAL Neutralizes all currently circulating Well-suited for administered as a LONG-TERM SOLUTION variant strains of subcutaneous injection COVID-19 in vivo. instead of an infusion. FOR COVID-19
Slide 9: Q1 2021 Financials Update
UPDATE Q1 2021 FINANCIALS
Slide 10: Partnership Business Growth Off to a Strong Start in 2021
Q 1 2 0 2 1 B U S I N E S S U P D A T E . F I N ANCIA L RES U LTS* PARTNERSHIP BUSINESS GROWTH – WITHOUT downstream participation + WITH downstream participation OFF TO A STRONG START IN 2021 # of Cumulative # of Cumulative # of Discovery Partners Programs Under Contract Program Starts 29 119 30 120
Slide 11: $202.7M Revenue Driven by COVID-19 Program and Trianni Licensing
Q 1 2 0 2 1 B U S I N E S S U P D A T E . F I N ANC IA L RES U LTS $202.7M REVENUE DRIVEN $202.7M BY COVID-19 PROGRAM AND TRIANNI LICENSING $171.5M Note associated $20M royalty fee expense Revenue USD ROYALTIES MILESTONE $7.0M LICENSING $20.3M Trianni $4.7M RESEARCH FEES $4.0M Q1 2020 Q1 2021
Slide 12: Operating Expenses Reflect Continued Strengthening of the Platform
Q 1 2 0 2 1 B U S I N E S S U P D A T E . F I N ANC IA L RES U LTS OPERATING EXPENSES REFLECT CONTINUED STRENGTHENING OF THE PLATFORM Operating Expenses USD RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN +$8.2M $12.4M +$4.8M $6.4M +$2.1M $4.1M $2.6M $1.7M $0.4M Q1 2020 Q1 2021 Q1 2020 Q1 2
Slide 13: Earnings Jumped to $117M: $0.43 Basic, $0.37 Diluted Per Share
Q 1 2 0 2 1 B U S I N E S S U P D A T E . F I N ANC IA L RES U LTS EARNINGS JUMPED TO $117M: EQUIVALENT TO $0.43 (BASIC), $0.37 (DILUTED) PER SHARE Earnings USD NET EARNINGS (LOSS) EARNINGS PER SHARE: BASIC EARNINGS PER SHARE: DILUTED $117.2M $0.43 $0.37 ($2.1M) ($0.01) ($0.01) Q1 2020 Q1 2021 Q1 20
Slide 14: Operations Results Financed Investments in Q1 & Further Strengthen Liquidity
Q 1 2 0 2 1 B U S I N E S S U P D A T E . F I N ANC IA L RES U LTS OPERATIONS RESULTS FINANCED INVESTMENTS IN Q1 & FURTHER STRENGTHEN LIQUIDITY Additionally, $193M accrued AR balance at quarter end Cash Flows USD $109.5M $12.2M Facilities $685.8M JV ($15.8M) ($1.5M) ($0.5M) $594.1M Cash & Operations
Slide 15: Thank You
ellera THANK YOU